EGFR and neoplasm: Furthermore, we found that EGFR internalization at tumor sites was associated with high rates of stable disease (SD) and PD (70.8% versus 30.8%, P = 0.036) as well as poor progression‐free survival (PFS) (Figure 1C,D).